| Title: |
Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT |
| Authors: |
Saraceni F.; Labopin M.; Raiola A. M.; Blaise D.; Remenyi P.; Sora F.; Pavlu J.; Bramanti S.; Busca A.; Berceanu A.; Battipaglia G.; Visani G.; Socie G.; Bug G.; Mico C.; La Nasa G.; Musso M.; Olivieri A.; Spyridonidis A.; Savani B.; Ciceri F.; Nagler A.; Mohty M. |
| Contributors: |
Saraceni, F.; Labopin, M.; Raiola, A. M.; Blaise, D.; Remenyi, P.; Sora, F.; Pavlu, J.; Bramanti, S.; Busca, A.; Berceanu, A.; Battipaglia, G.; Visani, G.; Socie, G.; Bug, G.; Mico, C.; La Nasa, G.; Musso, M.; Olivieri, A.; Spyridonidis, A.; Savani, B.; Ciceri, F.; Nagler, A.; Mohty, M. |
| Publisher Information: |
John Wiley and Sons Inc |
| Publication Year: |
2023 |
| Description: |
We conducted a registry analysis including adult acute myeloid leukemia (AML) patients in remission who had received thiotepa, busulfan, and fludarabine (TBF) or treosulfan-based (Treo) conditioning for haplo-hematopoietic stem cell transplant (HSCT) with posttransplant cyclophosphamide (PTCy) between 2010 and 2020. A total of 1123 patients met the inclusion criteria (968 received TBF and 155 received Treo). A 1:1 matched-pair analysis was performed on 142 TBF and 142 Treo patients. In the Treo group, 68% of patients received treosulfan at a dose ≥36 g/m2 and 54% of patients received a second alkylator (thiotepa or melphalan). We observed a trend toward increased incidence of grade II-IV acute (a) graft-versus-host disease (GVHD) at 180 days in the TBF group compared with Treo (29% versus 20%; P = 0.08), while incidence of grade III-IV aGVHD was not statistically different. Similarly, the incidence of chronic (c) GVHD was not statistically different in the 2 groups. Incidence of nonrelapse mortality at 2 years was 19% in TBF and 14% in Treo (P = 0.4). Relapse incidence at 2 years was not statistically different in the 2 groups (16% and 18% in TBF and Treo, respectively; P = 0.9). Leukemia-free survival, overall survival, and GVHD-free, relapse-free survival was 65% versus 68% (P = 0.6), 73% versus 76% (P = 0.5), and 54% versus 53% (P = 0.8) in TBF versus Treo, respectively. In conclusion, we did not find a significant difference between the 2 conditioning in the present study; Treo and TBF represent 2 valid alternative regimens for haplo-HSCT with PTCy for AML in remission. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/wos/WOS:001068171100001; volume:7; issue:10; numberofpages:8; journal:HEMASPHERE; https://hdl.handle.net/20.500.11768/164803; https://journals.lww.com/hemasphere/fulltext/2023/10000/thiotepa_busulfan_fludarabine_compared_to.6.aspx |
| DOI: |
10.1097/HS9.0000000000000952 |
| Availability: |
https://hdl.handle.net/20.500.11768/164803; https://doi.org/10.1097/HS9.0000000000000952; https://journals.lww.com/hemasphere/fulltext/2023/10000/thiotepa_busulfan_fludarabine_compared_to.6.aspx |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.AC927EC4 |
| Database: |
BASE |